Ceritinib
Sign in to save this workspacePrimary targets: ALK · FDA status: FDA Approved
Selectivity scorecard
KISS
95.44
Gini
0.618
CATDS
0.014
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ceritinib. Strongest target: FES_FPS at 99.8% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FES_FPS | 99.8% | 0.3% |
| 2 | STK22D_TSSK1 | 99.7% | 0.3% |
| 3 | LRRK2 | 99.4% | 0.6% |
| 4 | IRR_INSRR | 98.9% | 1.1% |
| 5 | FER | 98.4% | 1.6% |
| 6 | ALK | 98.3% | 1.7% |
| 7 | IGF1R | 98.1% | 1.9% |
| 8 | IR | 97.8% | 2.2% |
| 9 | ROS_ROS1 | 97.7% | 2.3% |
| 10 | TNK1 | 97.3% | 2.7% |
| 11 | TYK1_LTK | 97.3% | 2.7% |
| 12 | ACK1 | 97.2% | 2.8% |
| 13 | FAK_PTK2 | 96.4% | 3.6% |
| 14 | MYO3B | 94.4% | 5.6% |
| 15 | CAMKK2 | 92.7% | 7.3% |
| 16 | CLK1 | 92.1% | 7.9% |
| 17 | CLK2 | 91.1% | 8.9% |
| 18 | PHKG1 | 90.1% | 9.9% |
| 19 | PYK2 | 89.7% | 10.3% |
| 20 | STK32B_YANK2 | 89.3% | 10.7% |
Selectivity landscape
Where Ceritinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ceritinib.
Annotations
Sign in to read and post annotations.
Loading…